Basit öğe kaydını göster

dc.contributor.authorYarman, Sema
dc.contributor.authorUzum, Ayşe Kubat
dc.contributor.authorTelci, AYŞE GÜL SÜNDÜS
dc.contributor.authorTanakol, Refik
dc.contributor.authorBoztepe, Harika
dc.contributor.authorMert, Meral
dc.contributor.authorAral, Ferihan
dc.contributor.authorColak, Nese
dc.contributor.authorAlagol, Faruk
dc.contributor.authorTamer, Gonca
dc.date.accessioned2021-03-04T10:51:28Z
dc.date.available2021-03-04T10:51:28Z
dc.date.issued2012
dc.identifier.citationTamer G., Telci A. G. S. , Mert M., Uzum A. K. , Aral F., Tanakol R., Yarman S., Boztepe H., Colak N., Alagol F., "Prevalence of pituitary adenomas in macroprolactinemic patients may be higher than it is presumed", ENDOCRINE, cilt.41, sa.1, ss.138-143, 2012
dc.identifier.issn1355-008X
dc.identifier.otherav_6f4ba54a-afe4-4827-8cdc-eab0ac4ff55b
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/76818
dc.identifier.urihttps://doi.org/10.1007/s12020-011-9536-4
dc.description.abstractOne form of prolactin (PRL) is macroprolactin with high molecular mass. Many macroprolactinemic patients have no pituitary adenomas and no clinical symptoms of hyperprolactinemia, it is controversial whether macroprolactinemia is a benign condition that does not need further investigation and treatment. In this study, we aimed to compare macroprolactinemic patients (group I) with the true hyperprolactinemic patients (group II) for the presence of pituitary adenoma. We investigated 161 patients with hyperprolactinemia, whose magnetic resonance imaging records of the pituitary were taken. All patients were questioned for irregular menses, infertility and examined for galactorrhea. Patients were screened for macroprolactinemia by polyethylene glycol precipitation, and a recovery of a parts per thousand currency sign40% and normal monomeric PRL level was taken as an indication of significant macroprolactinemia. Of 161 patients with hyperprolactinemia, 60 (37.26%) had macroprolactinemia. PRL levels of group II were lower than those of group I (P = 0.011), although monomeric PRL levels of group II were higher than those of group I (P = 0.0005). Of 60 macroprolactinemic patients, 16 (26.7%) had pituitary adenomas. The prevalence of pituitary adenomas was lower in group I, compared with group II (P = 0.0005). No significant differences were found between the prevalences of irregular menses and infertility of group I and II (P = 0.084, P = 0.361). Prevalence of galactorrhea in group I was lower than that in group II (P = 0.048). Prevalence of pituitary adenomas in macroprolactinemic patients is lower compared with the true hyperprolactinemic patients, but may be higher than that found in other recent studies and in the general population.
dc.language.isoeng
dc.subjectEndokrinoloji ve Metabolizma Hastalıkları
dc.subjectİç Hastalıkları
dc.subjectDahili Tıp Bilimleri
dc.subjectSağlık Bilimleri
dc.subjectTıp
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectENDOKRİNOLOJİ VE METABOLİZMA
dc.titlePrevalence of pituitary adenomas in macroprolactinemic patients may be higher than it is presumed
dc.typeMakale
dc.relation.journalENDOCRINE
dc.contributor.departmentİstanbul Üniversitesi , ,
dc.identifier.volume41
dc.identifier.issue1
dc.identifier.startpage138
dc.identifier.endpage143
dc.contributor.firstauthorID27909


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster